161 related articles for article (PubMed ID: 33149867)
1.
Mohseni N; Roshan R; Naderi S; Behdani M; Kazemi-Lomedasht F
Iran J Basic Med Sci; 2020 Oct; 23(10):1335-1339. PubMed ID: 33149867
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy of angiogenesis using anti-VEGFR2 and anti-NRP-1 nanobodies.
Karami E; Naderi S; Roshan R; Behdani M; Kazemi-Lomedasht F
Cancer Chemother Pharmacol; 2022 Feb; 89(2):165-172. PubMed ID: 34988654
[TBL] [Abstract][Full Text] [Related]
3. Selection and characterization of specific nanobody against neuropilin-1 for inhibition of angiogenesis.
Naderi S; Roshan R; Ghaderi H; Behdani M; Mahmoudi S; Habibi-Anbouhi M; Shokrgozar MA; Kazemi-Lomedasht F
Mol Immunol; 2020 Dec; 128():56-63. PubMed ID: 33070092
[TBL] [Abstract][Full Text] [Related]
4. Effective blocking of neuropilin-1activity using oligoclonal nanobodies targeting different epitopes.
Karami E; Mesbahi Moghaddam M; Behdani M; Kazemi-Lomedasht F
Prep Biochem Biotechnol; 2023; 53(5):523-531. PubMed ID: 35984637
[TBL] [Abstract][Full Text] [Related]
5. Investigation of the therapeutic potential of recombinant bispecific bivalent anti-PD-L1/VEGF nanobody in inhibition of angiogenesis.
Hassanzadeh Eskafi A; Oghalaei A; Mahboudi F; Ghaderi H; Behdani M; Shoari A; Kazemi-Lomedasht F
Immunopharmacol Immunotoxicol; 2023 Apr; 45(2):197-202. PubMed ID: 36193665
[TBL] [Abstract][Full Text] [Related]
6. Oligoclonal selection of nanobodies targeting vascular endothelial growth factor.
Ahadi M; Ghasemian H; Behdani M; Kazemi-Lomedasht F
J Immunotoxicol; 2019 Dec; 16(1):34-42. PubMed ID: 30409071
[TBL] [Abstract][Full Text] [Related]
7. Efficient Inhibition of Pathologic Angiogenesis using Combination Therapy of Anti-Epcam and Anti-VEGFR2 Nanobodies.
Karami E; Azizi P; Behdani M; Kazemi-Lomedasht F
Curr Pharm Des; 2023; 29(13):1059-1066. PubMed ID: 37078346
[TBL] [Abstract][Full Text] [Related]
8. Development of a mono-specific anti-VEGF bivalent nanobody with extended plasma half-life for treatment of pathologic neovascularization.
Sadeghi A; Behdani M; Muyldermans S; Habibi-Anbouhi M; Kazemi-Lomedasht F
Drug Test Anal; 2020 Jan; 12(1):92-100. PubMed ID: 31476257
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of angiogenesis in human endothelial cell using VEGF specific nanobody.
Kazemi-Lomedasht F; Behdani M; Bagheri KP; Habibi-Anbouhi M; Abolhassani M; Arezumand R; Shahbazzadeh D; Mirzahoseini H
Mol Immunol; 2015 May; 65(1):58-67. PubMed ID: 25645505
[TBL] [Abstract][Full Text] [Related]
10.
Kazemi-Lomedasht F; Pooshang-Bagheri K; Habibi-Anbouhi M; Hajizadeh-Safar E; Shahbazzadeh D; Mirzahosseini H; Behdani M
Iran J Basic Med Sci; 2017 May; 20(5):489-496. PubMed ID: 28656083
[TBL] [Abstract][Full Text] [Related]
11. Development of a Recombinant Monospecific Anti-PLGF Bivalent Nanobody and Evaluation of it in Angiogenesis Modulation.
Nikooharf A; Arezumand R; Mansouri K; Khoshi AH; Namdar Ahmadabad H
Mol Biotechnol; 2020 Dec; 62(11-12):580-588. PubMed ID: 32975735
[TBL] [Abstract][Full Text] [Related]
12. Targeting Neuropilin-1 with Nanobodies Reduces Colorectal Carcinoma Development.
De Vlaeminck Y; Bonelli S; Awad RM; Dewilde M; Rizzolio S; Lecocq Q; Bolli E; Santos AR; Laoui D; Schoonooghe S; Tamagnone L; Goyvaerts C; Mazzone M; Breckpot K; Van Ginderachter JA
Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33266104
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of neovascularisation in human endothelial cells using anti NRP-1 nanobody fused to truncated form of diphtheria toxin as a novel immunotoxin.
Naderi S; Roshan R; Behdani M; Kazemi-Lomedasht F
Immunopharmacol Immunotoxicol; 2021 Apr; 43(2):230-238. PubMed ID: 33657977
[TBL] [Abstract][Full Text] [Related]
14. Design of a humanized anti vascular endothelial growth factor nanobody and evaluation of its
Kazemi-Lomedasht F; Muyldermans S; Habibi-Anbouhi M; Behdani M
Iran J Basic Med Sci; 2018 Mar; 21(3):260-266. PubMed ID: 29511492
[TBL] [Abstract][Full Text] [Related]
15. Dual Targeting of Endothelial and Cancer Cells Potentiates In Vitro Nanobody-Targeted Photodynamic Therapy.
Mashayekhi V; Xenaki KT; van Bergen En Henegouwen PMP; Oliveira S
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32977602
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
[TBL] [Abstract][Full Text] [Related]
17. A Novel Blood-Brain Barrier-Penetrating and Vascular-Targeting Chimeric Peptide Inhibits Glioma Angiogenesis.
Lu L; Wang L; Zhao L; Liao J; Zhao C; Xu X; Wang F; Zhang X
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240099
[TBL] [Abstract][Full Text] [Related]
18. DDA suppresses angiogenesis and tumor growth of colorectal cancer in vivo through decreasing VEGFR2 signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Oncotarget; 2016 Sep; 7(39):63124-63137. PubMed ID: 27517319
[TBL] [Abstract][Full Text] [Related]
19. Production and Characterization of Novel Camel Single Domain Antibody Targeting Mouse Vascular Endothelial Growth Factor.
Kazemi-Lomedasht F; Behdani M; Habibi-Anbouhi M; Shahbazzadeh D
Monoclon Antib Immunodiagn Immunother; 2016 Jun; 35(3):167-71. PubMed ID: 27167350
[TBL] [Abstract][Full Text] [Related]
20. Neuropilin-1 is required for endothelial cell adhesion to soluble vascular endothelial growth factor receptor 1.
Colotti G; Failla CM; Lacal PM; Ungarelli M; Ruffini F; Di Micco P; Orecchia A; Morea V
FEBS J; 2022 Jan; 289(1):183-198. PubMed ID: 34252269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
